Radiation device trial for skin cancer in patients with weak immune systems
Part of Cancer, Skin clinical trials.
This trial tests a special radiation device (DaRT) placed directly into skin cancer tumors. It is designed for patients with weakened immune systems (immunocompromised) who have a single skin cancer lesion on the skin (not spread elsewhere).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of skin cancer called cutaneous squamous cell carcinoma, confirmed by biopsy within the last 6 months.
- Your immune system is weakened due to a medical condition or treatment (like organ transplant, HIV, or certain medications).
- The tumor must be 7 cm or smaller (about the size of a lime or less) and located in a spot where the radiation seeds can be fully placed without hitting bone, major blood vessels, or vital organs.
- You must be willing to have multiple CT scans and agree to use effective birth control for one year after the procedure if you are able to have children.
- You cannot have had chemotherapy, immunotherapy, or radiation therapy in the last 4 weeks, and you cannot have other cancer that is growing or needs treatment.
- You must be generally healthy enough to undergo the procedure (ECOG score 0-2) and have a life expectancy of at least 12 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a radiation-emitting device placed near the tumor to treat certain malignant skin cancers that can be fully covered. It may help shrink or control the cancer at the skin site where the device is applied.
This trial tests a targeted radiation device (DaRT seeds) to treat certain cancers on the skin, in the mouth, or in superficial soft tissue. It may help when standard treatment (like surgery or regular radiation/chemo) hasn’t worked, isn’t safe, or isn’t wanted.
This trial studies a radiation-emitting device (DaRT) to treat certain cancers on the skin, in the mouth, or in superficial soft tissues. You may qualify if you have a confirmed malignant tumor, enough body strength for treatment, and blood tests and pregnancy status that meet safety limits.
This trial tests whether a targeted internal radiation treatment (DaRT) combined with pembrolizumab (an immune therapy) can shrink recurrent or metastatic head and neck squamous cell cancer that cannot be fully removed with surgery. It may help by making cancer more visible to the immune system while delivering localized radiation to a tumor area.
This trial studies DaRT, a treatment given before surgery, to improve outcomes for certain oral cavity squamous cell cancers that can be fully removed. You would be carefully selected using scans and tests to make sure the cancer is in the right place and you can safely receive the treatment.
This trial tests a device called DaRT that delivers alpha radiation directly to a recurrent glioblastoma tumor. It may help patients who cannot have surgery and have a single, small tumor regrowth.
Hear when a new Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.